

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM751179

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
REMPEX PHARMACEUTICALS, INC.		08/23/2022	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Silicon Valley Bank		
Street Address:	3003 Tasman Drive, HF 150		
City:	Santa Clara		
State/Country:	CALIFORNIA		
Postal Code:	95054		
Entity Type:	Corporation: CALIFORNIA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	85595007	CARBAVANCE	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	800-494-5225		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	Stewart Walsh		
Address Line 1:	1025 Connecticut Ave NW, Suite 712		
Address Line 2:	COGENCY GLOBAL Inc.		
Address Line 4:	Washington, D.C. 20036		
ATTORNEY DOCKET NUMBER:	1767838 TM B		
NAME OF SUBMITTER:	Gwendolyn Meccas		
SIGNATURE:	/Gwendolyn Meccas/		
DATE SIGNED:	08/25/2022		
Total Attachments: 14			
source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page1.tif			
source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd			

OP \$40.00 85595007

LMA)#page2.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page3.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page4.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page5.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page6.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page7.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page8.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page9.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page10.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page11.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page12.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page13.tif

source=B - Amended and Restated Intellectual Property Security Agreement (Rempex)- Melinta (3rd LMA)#page14.tif

AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Amended and Restated Intellectual Property Security Agreement (this “**Agreement**”) is entered into as of August 23, 2022, by and between SILICON VALLEY BANK, a California corporation (“**Bank**”) and REMPEX PHARMACEUTICALS, INC., a Delaware corporation (“**Grantor**”). This Agreement amends and restates in its entirety, and replaces, that certain Intellectual Property Security Agreement dated as of December 22, 2020, by and between Grantor and Bank (the “**Prior Agreement**”).

RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among Bank, Grantor, MELINTA THERAPEUTICS, LLC, a Delaware limited liability company (“**Melinta**”), MELINTA SUBSIDIARY CORP., a Delaware corporation (“**Subsidiary Corp.**”), and TARGANTA THERAPEUTICS CORPORATION, a Delaware corporation (“**Targanta**”, and together with Grantor, Melinta and Subsidiary Corp., individually and collectively, jointly and severally, “**Borrower**”) dated as of December 22, 2020, as amended by that certain First Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of May 3, 2022, as further amended by that certain Second Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of July 25, 2022, and as further amended by that certain Third Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of the date hereof (as the same has been, and as may be further amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in its Copyrights, Trademarks, and Patents (as each term is described below) to secure the obligations of Grantor to Bank.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Borrower’s obligations to Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. Subject to the terms and conditions of the Loan Agreement, to secure Borrower’s obligations to Bank, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property

(all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how and operating manuals now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) [Reserved];

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding anything to the contrary herein, the Intellectual Property Collateral shall not include any United States intent-to-use trademark or service mark applications filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, at all times prior to the filing of a “Statement

of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto with the United States Patent and Trademark Office or otherwise.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials of the United States to record and register this Agreement upon request by Bank.

3. Authorization. Grantor hereby authorizes Bank to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Prior Agreement. Grantor and Bank hereby agree that, effective upon the execution and delivery of this Agreement by each such party, the terms and provisions of the Prior Agreement shall be and hereby are amended, restated and superseded in their entirety by the terms and provisions of this Agreement. Nothing herein contained shall be construed as a substitution or novation of the obligations of Grantor outstanding under the Prior Agreement or instruments securing the same, which obligations shall remain in full force and effect, except to the extent that the terms thereof are modified hereby or by instruments executed concurrently herewith. Nothing expressed or implied in this Agreement shall be construed as a release or other discharge of Grantor from any of the obligations or liabilities under the Prior Agreement. Grantor hereby confirms and agrees that to the extent that the Prior Agreement purports to assign or pledge to the Bank, or to grant to Bank a security interest in or lien on, any collateral as security for the Obligations, such pledge, assignment or grant of the security interest or lien is hereby ratified and confirmed in all respects and shall remain effective as of the first date it became effective.

8. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and


construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

REMPEX PHARMACEUTICALS, INC.


By:  _____
05150EFB2D3345C...

Name: Christine Ann Miller

Title: President and Chief Executive Officer

BANK:

SILICON VALLEY BANK

By:  _____
C7937DD0BDA44B7...

Name: John Sansone

Title: Vice President

[Signature Page to Amended and Restated Intellectual Property Security Agreement (Rempex)]

TRADEMARK
REEL: 007821 FRAME: 0245

EXHIBIT A

Copyrights

Description

Registration/
Application
Number

Registration/
Application
Date

None.

EXHIBIT B

Patents

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
COMPOUND AND RESPECTIVE USE, PHARMACEUTICAL COMPOSITION, STERILE CONTAINER, AND METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION	Brazil	BR112013003045-3	08-Aug-2011	BR112013003045-3	31-Aug-2021
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Canada	2807546	08-Aug-2011		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Chile	399-2013	08-Aug-2011	57.867	06-Aug-2019
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Cyprus, Republic of	18183968.9	08-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Spain	11816882.2	08-Aug-2011	2603514	18-Jul-2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Spain	18183968.9	08-Aug-2011	3412676	12-Feb-2020
A CRYSTALLINE CYCLIC BORONIC ACID ESTER DERIVATIVE, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Hong Kong	42020022251.1	08-Aug-2011		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Israel	224564	08-Aug-2011	224564	29-May-2017
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Italy	11816882.2	08-Aug-2011	2603514	18-Jul-2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Japan	2013-524151	08-Aug-2011	6266978	05-Jan-2018

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Japan	2016-234146	08-Aug-2011	6602742	18-Oct-2019
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Japan	2019-185991	08-Aug-2011	6854861	18-Mar-2021
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Japan	2021-002699	08-Aug-2011		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Laos	PT234	08-Aug-2011		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Mexico	MX/a/2013/001517	08-Aug-2011	348653	21-Jun-2017
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Thailand	1301000670	08-Aug-2011		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Vietnam	1-2013-00725	08-Aug-2011	19985	01-Oct-2018
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	South Africa	2013/01014	08-Aug-2011	2013/01014	30-Oct-2013
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Spain	201930023	28-Mar-2019	201930023	29-Jan-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Spain	201930022	28-Mar-2019	201930022	29-Jan-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Greece	20190800016	28-Mar-2019	8000778	05-Aug-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Greece	20190800017	28-Mar-2019	8000779	05-Aug-2020

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Italy	132019000000049	28-Mar-2019	132019000000049	19-Aug-2019
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Italy	132019000000051	28-Mar-2019	132019000000051	19-Aug-2019
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Romania	c 2019 016	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Romania	c 2019 015	29-Mar-2019		
VABORBACTAM	Slovenia	C202040021	09-Jul-2020	C202040021	26-Aug-2020
VABORBACTAM/MEROPENEM	Slovenia	C202040020	09-Jul-2020	C202040020	14-Sep-2020
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Spain	15788682.1	30-Apr-2015	3140310	07-Aug-2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Hong Kong	42020013257.9	30-Apr-2015		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Italy	15788682.1	30-Apr-2015	3140310	07-Aug-2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Monaco	15788682.1	30-Apr-2015	3140310	07-Aug-2019
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	San Marino	15788682.1	30-Apr-2015	3140310	07-Aug-2019
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	Spain	15870720.8	09-Dec-2015	3233869	25-Sep-2019
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVES	Italy	15870720.8	09-Dec-2015	3233869	25-Sep-2019
METHODS OF TREATING BACTERIAL INFECTIONS	Canada	2982911	20-Apr-2016		
METHODS OF TREATING BACTERIAL INFECTIONS	Japan	2017-555494	20-Apr-2016	6945452	16-Sep-2021

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
METHODS OF TREATING BACTERIAL INFECTIONS	Japan	2021-101472	20-Apr-2016		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	United Arab Emirates	P6001091/2019	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Brazil	BR112019015577-5	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Brazil	BR122021000357-2	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Canada	3052277	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Chile	02164-2019	31-Jan-2018	62933	03-Jun-2021
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Chile	01209-2020	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Colombia	NC2019/0009018	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Colombia	NC2021/0017310	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Algeria	190402	31-Jan-2018	10844	05-Apr-2021
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Egypt	1215/2019	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Hong Kong	62020008149.0	31-Jan-2018		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Jordan	PCT/JO/2019/188	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Japan	2019-562237	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Mexico	MX/a/2019/009136	31-Jan-2018		
APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE	Saudi Arabia	519402378	31-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Brazil	BR112019014089-1	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Canada	3048650	08-Jan-2018		
USE OF A PHARMACEUTICAL COMBINATION OF VABORBACTAM AND MEROPENEM, FOR TREATING OR AMELIORATING COMPLICATED URINARY TRACT INFECTION OR ACUTE PYELONEPHRITIS	Chile	01918-2019	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Chile	01886-2020	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Algeria	190408	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Hong Kong	62020007455.2	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Japan	2019-537269	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Mexico	MX/a/2019/008281	08-Jan-2018	390529	03-Mar-2022
METHODS OF TREATING BACTERIAL INFECTIONS	Mexico	MX/a/2022/001704	08-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Thailand	1901004236	08-Jan-2018		
TETRACYCLINE COMPOSITIONS	Austria	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE	Belgium	11781314.7	12-May-	2568987	16-Nov-

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
COMPOSITIONS			2011		2016
PHARMACEUTICAL COMPOSITIONS AND RESPECTIVE USES, PREPARATION METHODS, AND KIT	Brazil	BR1120120285246	12-May-2011	BR112012028524-6	15-Mar-2022
TETRACYCLINE COMPOSITIONS	Canada	2799079	12-May-2011	2799079	15-Jan-2019
TETRACYCLINE COMPOSITIONS	Switzerland	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Chile	3168-2012	12-May-2011	CL56.663	07-Nov-2018
TETRACYCLINE COMPOSITIONS	Czech Republic	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Germany	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Denmark	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Spain	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Finland	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	France	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	United Kingdom	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Greece	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Hungary	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Ireland	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Israel	222896	12-May-2011	222896	01-Jul-2017
TETRACYCLINE COMPOSITIONS	Italy	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Japan	2013-510322	12-May-2011	6025712	21-Oct-2016
TETRACYCLINE COMPOSITIONS	Liechtenstein	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Mexico	MX/a/2012/012993	12-May-2011	347919	17-May-2017
TETRACYCLINE COMPOSITIONS	Netherlands	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Norway	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Poland	11781314.7	12-May-2011	2568987	16-Nov-2016

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
TETRACYCLINE COMPOSITIONS	Portugal	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Romania	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Sweden	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	Turkey	11781314.7	12-May-2011	2568987	16-Nov-2016
TETRACYCLINE COMPOSITIONS	South Africa	2012/08466	12-May-2011	2012/08466	19-Dec-2018
CO-ADMINISTRATION OF MINOCYCLINE AND COLISTIN TO REDUCE ACUTE KIDNEY INJURY	Canada	3071096	08-Jan-2018		
CO-ADMINISTRATION OF MINOCYCLINE AND COLISTIN TO REDUCE ACUTE KIDNEY INJURY	European Patent Convention	18736291.8	08-Jan-2018		
CO-ADMINISTRATION OF MINOCYCLINE AND COLISTIN TO REDUCE ACUTE KIDNEY INJURY	Hong Kong	62020009940.1	08-Jan-2018		
Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections	United States of America	11/856657	09/17/2007	7994225	08/09/2011
Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof	United States of America	12/613329	11/05/2009	8178490	05/15/2012
Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof	United States of America	12/116164	05/06/2008	8268865	09/18/2012
Therapeutic uses of Tigemonam and Carumonam	United States of America	13/797509	03/12/2013	Pending	Pending
Oxamazin Antibiotics	United States of America	13/829304	03/14/2013	Pending	Pending
Methods of Treating Bacterial Infections	United States of America	14/377163	02/11/2013	Pending	Pending

EXHIBIT C

Trademarks

Trademark	Country Name	App. No.	App. Date	Reg. No.	Reg. Date
CARBAVANCE	USA	85595007	04/11/2012	4777486	07/21/2015

NY:2426117